Arvinas, Novartis collaborate for development, commercialization of ARV-766 for prostate cancer
New Haven: Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, has announced it has entered into an exclusive strategic license agreement with Novartis for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. The transaction also […]